ZA87560B - Compound for the manufacture of a therapeutic agent - Google Patents

Compound for the manufacture of a therapeutic agent

Info

Publication number
ZA87560B
ZA87560B ZA87560A ZA87560A ZA87560B ZA 87560 B ZA87560 B ZA 87560B ZA 87560 A ZA87560 A ZA 87560A ZA 87560 A ZA87560 A ZA 87560A ZA 87560 B ZA87560 B ZA 87560B
Authority
ZA
South Africa
Prior art keywords
manufacture
compound
therapeutic agent
treatment
conditions
Prior art date
Application number
ZA87560A
Inventor
David Frederick Horrobin
Original Assignee
Efamol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Ltd filed Critical Efamol Ltd
Publication of ZA87560B publication Critical patent/ZA87560B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

This invention relates to the treatment of presenile or senile dementia and in particular to the treatment of Alzheimer's disease. It is proposed that such conditions may be combatted or their effects alleviated by the administration of a physiologically acceptable lithium compound and/or of an essential fatty acid or a physiologically acceptable salt thereof and there is described herein the use of lithium compounds and/or essential fatty acids or salts thereof for the manufacture of therapeutic agents for combatting such conditions.
ZA87560A 1986-01-27 1987-01-26 Compound for the manufacture of a therapeutic agent ZA87560B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868601915A GB8601915D0 (en) 1986-01-27 1986-01-27 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA87560B true ZA87560B (en) 1987-09-30

Family

ID=10591997

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA87560A ZA87560B (en) 1986-01-27 1987-01-26 Compound for the manufacture of a therapeutic agent

Country Status (13)

Country Link
US (2) US4753964A (en)
EP (1) EP0234733B1 (en)
JP (1) JPS62185018A (en)
AT (1) ATE69378T1 (en)
AU (1) AU593317B2 (en)
DE (1) DE3774449D1 (en)
ES (1) ES2040242T3 (en)
GB (1) GB8601915D0 (en)
GR (1) GR3003120T3 (en)
HK (1) HK127893A (en)
IE (1) IE59606B1 (en)
SG (1) SG114293G (en)
ZA (1) ZA87560B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120763A (en) * 1986-11-26 1992-06-09 Bar Ilan University Physiologically active and nutritional composition
US5599840A (en) * 1986-11-26 1997-02-04 Bar Ilan University Physiologically active and nutritional composition
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
ES2040847T3 (en) * 1987-04-27 1996-07-16 Efamol Holdings A PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION CONTAINING A LITHIUM SALT.
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
US4851398A (en) * 1987-09-30 1989-07-25 Elena Avram Bismuth containing pharmaceutical compositions
JP2524217B2 (en) * 1988-04-18 1996-08-14 マルハ株式会社 Brain function improving composition, learning ability enhancing agent, memory enhancing agent, dementia preventive agent or dementia therapeutic agent
AT397201B (en) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr USE OF THE ENZYME COFACTOR NADPH IN THE PRODUCTION OF A MEDICINAL PRODUCT
AT397200B (en) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr USE OF SELENIUM METHIONINE IN THE PRODUCTION OF A MEDICINAL PRODUCT
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
IL91802A (en) * 1988-10-27 1994-05-30 Univ Bar Ilan Compositions containing linolenic acid derivativesfor treating Alzheimer's disease, related dementias and epilepsy
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
ZA92452B (en) * 1991-01-24 1992-10-28 Martek Corp Microbial oil mixtures and uses thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
JPH08511005A (en) * 1993-06-01 1996-11-19 コーテックス ファーマシューティカルズ インコーポレイテッド Alkaline or acid phosphatase inhibitors in the treatment of neurological disorders
ATE446101T1 (en) * 1993-06-09 2009-11-15 Martek Biosciences Corp USE OF DOCOSAHEXAENIC ACID FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF SENIL DEMENTIA AND ALZHEIMER'S DISEASE
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU1067795A (en) * 1993-11-26 1995-06-13 Karla Lehmann Use of lithium compounds in the treatment and prevention of alzheimer's disease
JPH07143862A (en) * 1994-05-06 1995-06-06 Maruha Corp Functional food having cerebral function-improving effect
EP0726073A3 (en) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmaceutical compositions containing at least one of haloperidol, imipramine or trifluoroperazine
FR2740342B1 (en) * 1995-10-26 1997-12-19 Oreal USE OF LANTHANIDE, MANGANESE, LITHIUM, TIN, ZINC OR YTTRIUM SALT, COBALT, BARIUM, STRONTIUM IN PHARMACEUTICAL COMPOSITIONS
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
SK285210B6 (en) * 1996-10-11 2006-09-07 Scarista Limited A pharmaceutical preparation for the treatment of schizophrenia and use of an oil comprising eicosapentaenoic or stearidonic acid, or combination thereof in the manufacture of the medicament
JPH11279066A (en) * 1998-03-25 1999-10-12 Mitsubishi Chemical Corp Neurocyte death suppressant containing lithium salt as active ingredient
JP4669095B2 (en) * 1999-07-19 2011-04-13 太陽化学株式会社 Composition for suppressing behavioral problems in pets
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP2003048831A (en) 2001-08-02 2003-02-21 Suntory Ltd Composition having preventing and ameliorating action on symptom or disease caused by decrease in brain function
NL1019368C2 (en) 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
ITMI20040069A1 (en) * 2004-01-21 2004-04-21 Tiberio Bruzzese USE OF HIGH CONCENTRATION N-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
JP4993852B2 (en) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 Composition having a preventive or ameliorating effect on symptoms or diseases accompanied by behavioral abnormalities caused by stress
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
HUE031206T2 (en) * 2005-05-23 2017-06-28 Massachusetts Inst Technology Compositions containing pufa and methods of use thereof
JP5967855B2 (en) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 Composition having an activity of reducing daytime activity and / or depressive symptoms
CN101262863B (en) * 2005-07-08 2016-08-31 Dsmip资产公司 For treating the polyunsaturated fatty acid of dull-witted and front dull-witted associated conditions
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
ES2277557B1 (en) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
WO2007086931A1 (en) * 2006-01-24 2007-08-02 Majid Fotuhi Dosage regimen and medicament for preventing of reducing risk of onset or progression of dementia by administration of specific vitamins and nsaid
CN101478977B (en) 2006-03-29 2013-03-27 维拉科治疗学控股有限公司 Treatment of neurodegenerative diseases
KR101578498B1 (en) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 Nerve regeneration agent
US20080181937A1 (en) * 2007-01-29 2008-07-31 Majid Fotuhi Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard)
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
KR101397554B1 (en) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 Compositions and method for the diagnosis, prevention and treatment of Alzheimer's disease
KR100852962B1 (en) * 2007-11-12 2008-08-20 주식회사 뉴로테크 Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts
BRPI1000970A2 (en) * 2010-04-07 2011-11-29 Fundacao Arnaldo Vieira De Carvalho pharmaceutical composition for the treatment of Alzheimer's disease, process for its obtaining and use
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
WO2015147742A1 (en) * 2014-03-24 2015-10-01 Kaohsiung Chang Gung Memorial Hospital Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment
JP2016023163A (en) * 2014-07-22 2016-02-08 出光興産株式会社 AGENT FOR REDUCING OXIDATIVE STRESS ON NERVE CELLS COMPRISING γ-LINOLENIC ACID
RU2587617C1 (en) * 2014-12-23 2016-06-20 Ольга Алексеевна Громова Method for preventing and treating neurodegenerative pathology and vascular dementia
WO2016191323A1 (en) 2015-05-22 2016-12-01 University Of South Florida Lithium co-crystals for treatment of neuropsychiatric disorders
CN109562089A (en) * 2016-06-13 2019-04-02 心悦生医股份有限公司 Lithium benzoate is used to treat the purposes of central nervous system disease
US20200113854A1 (en) * 2017-05-30 2020-04-16 Morinaga Milk Industry Co., Ltd. Composition for Improving Brain Function
US20220211700A1 (en) * 2019-05-23 2022-07-07 Indiana University Research And Technology Corporation Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels

Also Published As

Publication number Publication date
AU6767587A (en) 1987-07-30
US4810497A (en) 1989-03-07
JPS62185018A (en) 1987-08-13
EP0234733B1 (en) 1991-11-13
SG114293G (en) 1994-01-21
HK127893A (en) 1993-11-26
ES2040242T3 (en) 1993-10-16
IE870194L (en) 1987-07-27
IE59606B1 (en) 1994-03-09
DE3774449D1 (en) 1991-12-19
AU593317B2 (en) 1990-02-08
GB8601915D0 (en) 1986-03-05
GR3003120T3 (en) 1993-02-17
ATE69378T1 (en) 1991-11-15
EP0234733A1 (en) 1987-09-02
US4753964A (en) 1988-06-28

Similar Documents

Publication Publication Date Title
ZA87560B (en) Compound for the manufacture of a therapeutic agent
HUT71889A (en) Pharmaceutical compositions containing terfenadine metabolites and their optically pure isomers for treating allergic disorders
CA2133998A1 (en) Treatment of macular degeneration
DE69125216D1 (en) Aminoalkanesulfonic acid derivatives and pharmaceutical compositions thereof for the prevention or treatment of heart diseases
ATE135909T1 (en) METHOD FOR TREATING ACNE
EP0328634B1 (en) Pharmaceutical compositions for the treatment of psoriasis
IL90056A (en) Topical pharmaceutical compositions containing 4-quinoline carboxylic acid derivatives
KR950000141A (en) Use of L-carnitine O-esters containing aromatic acids for the preparation of pharmaceutical compositions for the treatment of skin diseases
DE2967356D1 (en) Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
DE69207479D1 (en) Use of the esters of acyl-L-carnitine with gamma-hydroxy-butyric acid for the production of pharmaceutical compositions for the treatment of liver diseases
ES8707111A1 (en) Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases
MY104521A (en) Treatment of depression.
DE69315162D1 (en) Use of L-carnitine and acyl-L-carnitine for the treatment of patients suffering from AIDS-related syndromes and of asymptomatic HIV-seropositive patients
IL103799A (en) Fish production
DE3467705D1 (en) Use of 4,5'-azo-bis-salicylic acid for the manufacture of a medicament for the treatment of inflammatory disorders in the intestine
GR3006606T3 (en)
IT1210874B (en) MAGNESIUM SALT OF KENODEXOXYLIC ACID AND URSODEXOXYLIC ACID, PROCESS FOR LASUAL PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN IT AS AN ACTIVE INGREDIENT.
DE345883T1 (en) USE OF DAPIPRAZOLE FOR PRODUCING A MEDICINAL PRODUCT TO PREVENT TOLERANCE DEVELOPMENT IN ANALGETIC TREATMENT WITH MORPHINE.
DE3681289D1 (en) COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR TOPICAL TREATMENT OF PARADENTAL DISEASES.
ES2058315T3 (en) EFFECTIVE COMPOUNDS AGAINST BRAIN FAILURE.
ZA884053B (en) Treating agents for renal diseases
RU93058599A (en) NEW DIMETHYLAMINE-OXYALCANDIPHOSPHONIC ACIDS AND THEIR SALTS, METHOD FOR PRODUCING THERE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS, APPLICATION